ID
38908
Description
Study ID: 110951 Clinical Study ID: 110951 Study Title: A two-part, randomised, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of intravenously infused GSK1995057 in healthy subjects. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01476046 See https://clinicaltrials.gov/ct2/show/NCT01476046 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: N/A, Placebo Trade Name: N/A Study Indication: Respiratory Disorders This phase I trial primarily studies the safety and tolerability of ascending single intravenous doses of the selective TNFR1 antagonist GSK1995057 in healthy volunteers, and secondly explores the drug's pharmacodynamics, pharmacokinetics, concentration in lung epithelial lining fluid as well as its effect on immune system markers. The drug is hypothesized to be useful for Acute Lung Injury. The single-centre study consists of two parts A and B with seven cohorts/ten subcohorts in total. Part A includes ascending doses of the investigational product given to subjects negative or positive for pre-existing human anti-heavy chain variable domain (HAVH) antibodies (Cohorts 1 to 3 with Subcohorts 1a, 2a and 3a negative for HAVH and 1b, 2b, 3b positive for HAVH). Part B includes only subjects negative for HAVH, with ascending doses given to Cohorts 4 to 6. Cohort 7 receives the same dose as Cohort 6, but whereas the other Cohorts are single-blinded, Cohort 7 is open-label and additionally receives a bronchoalveolar lavage (BAL). The study consists of a Screening Visit (up to 56 days before Day 1, the day of the drug administration), Visits on Day -1, 1, 2, 3, 5, 7, 14, 28 and Follow-Up Visits on Day 57 and 85. This form is to be filled in (repeatedly, if necessary) during the study and/or at the end of the study in case of non-serious adverse events.
Lien
https://clinicaltrials.gov/ct2/show/NCT01476046
Mots-clés
Versions (3)
- 22/10/2019 22/10/2019 -
- 22/10/2019 22/10/2019 -
- 12/11/2019 12/11/2019 - Sarah Riepenhausen
Détendeur de droits
GlaxoSmithKline
Téléchargé le
12 novembre 2019
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY-NC 3.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Phase I Trial of Intravenous TNFR1 Antagonist GSK1995057 in Healthy Subjects - NCT01476046
Non-serious AE
- StudyEvent: ODM
Description
Non-serious adverse event
Alias
- UMLS CUI-1
- C1518404
Description
Hidden
Type de données
text
Alias
- UMLS CUI [1,1]
- C2348184
- UMLS CUI [1,2]
- C1518404
Description
Diagnosis or Sign/Symptom
Type de données
text
Alias
- UMLS CUI [1]
- C0011900
- UMLS CUI [2]
- C3540840
Description
Hidden
Type de données
text
Alias
- UMLS CUI [1]
- C2826798
Description
Hidden
Type de données
text
Alias
- UMLS CUI [1]
- C1140263
Description
Hidden
Type de données
text
Alias
- UMLS CUI [1]
- C3898442
Description
Hidden
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0805701
- UMLS CUI [1,2]
- C0231175
Description
Start Date/Time
Type de données
partialDatetime
Alias
- UMLS CUI [1]
- C2826806
Description
if Recovered/Resolved (with or without sequelae) provide End Date and Time
Type de données
integer
Alias
- UMLS CUI [1]
- C1705586
Description
if applicable
Type de données
partialDatetime
Alias
- UMLS CUI [1]
- C2826793
Description
Non-serious adverse event frequency
Type de données
integer
Alias
- UMLS CUI [1,1]
- C0439603
- UMLS CUI [1,2]
- C1518404
Description
[hidden]
Type de données
text
Alias
- UMLS CUI [1]
- C1710066
Description
Adverse Event Maximum Grade
Type de données
text
Alias
- UMLS CUI [1,1]
- C0441799
- UMLS CUI [1,2]
- C1710066
Description
[hidden]
Type de données
text
Alias
- UMLS CUI [1,1]
- C0441799
- UMLS CUI [1,2]
- C1710066
- UMLS CUI [2,1]
- C0518690
- UMLS CUI [2,2]
- C1518404
Description
Action regarding Investigational Product because of non-serious adverse event
Type de données
text
Alias
- UMLS CUI [1,1]
- C1704758
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C1518404
Description
subject withdrawal because of non-serious adverse event
Type de données
text
Alias
- UMLS CUI [1,1]
- C0422727
- UMLS CUI [1,2]
- C0566251
- UMLS CUI [1,3]
- C1518404
Description
AE possibly caused by investigational product
Type de données
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0085978
- UMLS CUI [1,3]
- C1518404
Description
[hidden] If AE start and end time are used this item must be hidden.
Type de données
time
Alias
- UMLS CUI [1,1]
- C0449238
- UMLS CUI [1,2]
- C1518404
Description
[hidden]
Type de données
time
Alias
- UMLS CUI [1,1]
- C1272706
- UMLS CUI [1,2]
- C1517741
- UMLS CUI [1,3]
- C0178602
- UMLS CUI [1,4]
- C0439659
- UMLS CUI [1,5]
- C1518404
Similar models
Non-serious AE
- StudyEvent: ODM
C1264639 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C3540840 (UMLS CUI [2])
C0231175 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C1710066 (UMLS CUI [1,2])
C0518690 (UMLS CUI [2,1])
C1518404 (UMLS CUI [2,2])
C0566251 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C0566251 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C0085978 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C1518404 (UMLS CUI [1,2])
C1517741 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,3])
C0439659 (UMLS CUI [1,4])
C1518404 (UMLS CUI [1,5])